![](\"https:\/\/mms.businesswire.com\/media\/20260507499585\/en\/2530242\/5\/Seek_Labs_Logo_Lower_Color.jpg\"){kind=logo}
<\/a><\/a>\nMolecular diagnostics are widely considered the gold standard for disease detection, but they perform poorly outside the lab because they require centralized laboratory infrastructure for amplification methods, such as thermal cycling (PCR) and conventional isothermal techniques. Seek Amplification\u2122, Seek Labs' proprietary amplification chemistry, was engineered to reduce temperature and instrumentation constraints. ANINA, built on the Seek Amplification platform, removes the equipment requirement altogether, enabling detection-ready amplification under true point-of-care conditions and creating a foundation for decentralized molecular testing.<\/p>
\nThe patented approach introduces an asymmetric, semi-nested primer design in which two primers target regions upstream of the target sequence on one strand and a third primer targets the complementary strand. By combining this semi-nested architecture with a defined primer ratio, the system enables a single-reaction amplification process that preferentially generates single-stranded amplicons containing the target sequence. This architecture supports integration with downstream reporter-based detection formats, including fluorescent and electrochemical approaches.<\/p>
\n\u201cThis patent underscores our approach to bringing high-performance molecular detection closer to the point of care,\u201d said Jared Bauer, CEO of Seek Labs. \u201cInstead of adapting legacy amplification methods, we have re-engineered the chemistry itself. By eliminating the need for equipment and simplifying the amplification workflow, Seek Amplification can create a path for molecular testing to move beyond centralized labs and into the places where real-world decisions are made.\u201d<\/p>
\nThis chemistry is designed to enable molecular detection in decentralized and point-of-care settings where speed, simplicity, and accuracy are critical. It also forms the core amplification component within the company\u2019s SeekIt\u2122 platform, which supports flexible assay design across infectious disease targets and enables integration into both instrument-assisted and instrument-free formats. This positions SeekIt as a scalable platform for distributed molecular diagnostics.<\/p>
\nThis patent establishes foundational intellectual property for Seek Labs\u2019 amplification chemistry platform as the company advances applications in respiratory and other infectious disease diagnostics.<\/p>
\nAbout SeekIt\u2122<\/b><\/p>
\nSeekIt is Seek Labs\u2019 molecular point-of-care diagnostics platform designed to bring testing out of laboratories and to the point of care. Built for speed, accuracy, portability, and scalability, SeekIt integrates nucleic acid extraction and amplification as well as detection into a streamlined system that can support rapid deployment across clinical, public health, and field environments.<\/p>
\nAbout Seek Labs<\/b><\/p>
\nEvery disease has a sequence. Seek Labs is a TechBio company building the systems to decode, program, and resolve diseases. At the core of this system is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers across Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop where genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.<\/p>
\nHeadquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah\u2019s collaborative life sciences ecosystem. Together with our partners, we\u2019re building faster, smarter solutions for the world\u2019s most urgent health challenges.<\/p>